17,261 trials
HIV Infections
Primary: Change From Baseline to 24 Weeks in HIV DNA (Log-10 Copies/10^6 Cells) as Measured by HIV DNA Within CD14+ Peripheral Blood Mononuclear Cells — 0.58 Log-10 copies/10^6…
Metastatic Renal Cell Carcinoma
Primary: Number of Subjects With Treatment-emergent Adverse Events — 3; 3; 6; 3 participants
Soft Tissue Sarcoma
Primary: Progression Free Survival (PFS) at 12 Weeks — 46.9; 31.6; 21.1; 19.2 Percentage of participants
Breast Cancer
Primary: Proportion of Patients Experiencing Grade 3 or 4 Diarrhea as Measured by NCI CTCAE v3.0 — 43 percentage of patients
Waldenstrom's Macroglobulinemia
Primary: Overall Response Rate — 25 Participants
Esophageal Cancer
Primary: Progression-free Survival Rate — 7 weeks
Asthma
Primary: Change From Baseline in Trough FEV1 (L) in Non-atopic Patients at Week 12 - Full Analysis Set — 0.05; 0.03 liter — p=0.7269
Tumor Pathway Activations Inhibited by Dovitinib
Primary: Clinical Benefit Rate (CBR) — 0; 1; 10; 11 number of participants
Crohn's Disease
Primary: Number of Participants With On-Treatment Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), and Discontinuations Due to AEs — 171; 58; 54 participants
Triple-negative Breast Cancer
Primary: 3-month Progression-free Survival (3-mo PFS) Rate — 0.511 proportion of participants
Follicular Lymphoma · Marginal Zone Lymphoma · Small Lymphocytic Lymphoma
Primary: Efficacy: Complete Response Rate (CRR) — 9.5 percentage of patients
Recurrent Non-Small Cell Lung Carcinoma · Stage IB Non-Small Cell Lung Carcinoma · Stage IIA Non-Small Cell Lung Carcinoma
Primary: Change in 18F-Fluorothymidine (FLT) Uptake — -0.4 SULmax
Idiopathic Pulmonary Fibrosis
Primary: Effect of Gefapixant on BP — 122; 76 units on a scale
Recurrent Melanoma
Primary: 2-year Local Recurrence Rate (LRR)/Incidence of Local Recurrence — 10 percentage of patients with LR
Aplastic Anemia
Primary: Incidence of Chronic GVHD — 5 number participants with chronic GVHD